Get the Stockscreener App
2.965
5.12%
-0.16
Inozyme Pharma Inc stock is traded at $2.965, with a volume of 281.00K.
It is down -5.12% in the last 24 hours and down -46.48% over the past month.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
See More
Previous Close:
$3.125
Open:
$3.1
24h Volume:
281.00K
Relative Volume:
1.06
Market Cap:
$194.01M
Revenue:
-
Net Income/Loss:
$-71.17M
P/E Ratio:
-1.9129
EPS:
-1.55
Net Cash Flow:
$-70.97M
1W Performance:
-25.88%
1M Performance:
-46.48%
6M Performance:
-35.54%
1Y Performance:
-9.05%
1-Day Range:
$2.95
$3.205
1-Week Range:
$2.95
$3.99
52-Week Range:
$2.95
$7.795
Inozyme Pharma Inc Stock (INZY) Company Profile
Name
Inozyme Pharma Inc
Sector
Industry
Phone
857-330-4340
Address
321 SUMMER STREET, BOSTON
Compare INZY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| INZY | 2.965 | 194.01M | 0 | -71.17M | -70.97M | -1.55 |
| VRTX | 466.78 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 759.96 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.96 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 231.32 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.42 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Initiated | Stifel | Buy |
| Aug-13-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| Mar-23-23 | Upgrade | Jefferies | Hold → Buy |
| May-26-22 | Initiated | Jefferies | Hold |
| Feb-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-29-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Inozyme Pharma Inc Stock (INZY) Latest News
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St
Inozyme Pharma stock hits 52-week low at $3.23 amid market shifts - Investing.com
Eventide Asset Management's Strategic Acquisition of Inozyme Pha - GuruFocus.com
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - Yahoo Finance
Inozyme Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
Inozyme Pharma CEO to Present at Stifel and Jefferies Healthcare Conferences | INZY Stock News - StockTitan
Inozyme Pharma’s (INZY) Buy Rating Reiterated at HC Wainwright - Defense World
Inozyme Pharma (NASDAQ:INZY) Given “Outperform” Rating at Wedbush - Defense World
FY2024 EPS Estimates for Inozyme Pharma Increased by Analyst - Defense World
Inozyme Pharma FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
FY2024 EPS Estimates for Inozyme Pharma Raised by Analyst - MarketBeat
Piper Sandler raises Inozyme Pharma target to $43 from $40 - Investing.com India
Inozyme Pharma's (INZY) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Inozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Inozyme Pharma’s Q3 2024 Financial and Clinical Progress - TipRanks
Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.com - Investing.com Canada
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Inozyme Pharma Reports Wider Q3 Loss, Advances Key Clinical Trials Despite $24.6M Loss | INZY Stock News - StockTitan
Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports positive trial results for kidney disease therapy - Investing.com India
Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada
Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire
The Manufacturers Life Insurance Company Grows Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
(INZY) Proactive Strategies - Stock Traders Daily
Inozyme Pharma presents kidney disease study at ASN Kidney Week By Investing.com - Investing.com Nigeria
Inozyme Pharma presents kidney disease study at ASN Kidney Week - Investing.com
Inozyme Pharma Announces Presentation of Interim Data from - GlobeNewswire
Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 6.9% - MarketBeat
Dimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Millennium Management LLC Acquires 1,084,341 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Cubist Systematic Strategies LLC Invests $84,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma appoints new board member - Investing.com
Inozyme Pharma appoints new board member By Investing.com - Investing.com South Africa
Inozyme Pharma Welcomes New Director Erik Harris - TipRanks
Inozyme appoints Erik Harris to board of directors - TipRanks
Inozyme Pharma Appoints Erik Harris to its Board of Directors - citybiz
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its - The Bakersfield Californian
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors - GlobeNewswire
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of - EIN News
How the (INZY) price action is used to our Advantage - Stock Traders Daily
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by American Century Companies Inc. - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Deerfield Management Company L.P. Series C Takes Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Blue Owl Capital Holdings LP Cuts Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Inozyme Pharma Inc Stock (INZY) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):